Jade Biosciences, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Jade Biosciences, Inc. (JBIO) is a clinical-stage biotechnology company developing novel monoclonal antibody therapies targeting inflammation and immunology indications for patients with autoimmune diseases. The company offers a pipeline including JADE101, a potentially best-in-class anti-APRIL monoclonal antibody in Phase 1 clinical trials for immunoglobulin A nephropathy (IgAN); JADE201, a half-life extended, afucosylated anti-BAFF-R monoclonal antibody with a dual mechanism of action for multiple systemic autoimmune diseases, with a first-in-human trial planned for the first half of 2026; and JADE-003, an undisclosed preclinical antibody discovery program targeting autoimmune indications, with a planned first-in-human trial in the first half of 2027. Programs build on assets licensed from Paragon Therapeutics. Jade Biosciences, founded in 2024 and headquartered at 221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts, operates primarily in the United States. Recent developments include the dosing of the first cohort in the Phase 1 healthy volunteer trial of JADE101 in September 2025, with interim biomarker data expected in the first half of 2026 to inform dosing for patient studies; the unveiling of JADE201 in October 2025; the completion of a $135 million private placement financing in October 2025 led by new and existing healthcare investors, extending cash runway into the first half of 2028; and a licensing agreement with Paragon Therapeutics in early October 2025 for exclusive rights to BAFF-R targeting antibodies, including up to $22 million in potential milestones. Earlier milestones encompass an $80 million Series A financing upon launch in August 2024 and a merger with Aerovate Therapeutics completed in April 2025 alongside a $300 million private placement. The company presented preclinical safety data and translational analyses for JADE101 at the American Society of Nephrology Kidney Week in November 2025.
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences Announces Proposed Underwritten Public Offering
Jade Biosciences' JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
Why Is Jade Biosciences Stock Trading Lower On Monday?
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jade Biosciences Appoints Edward R. Conner, M.D.
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript